Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03229499 · ClinicalTrials.gov registry record · Phase 2
Pulmonary Hypertension and Anastrozole Trial
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT03229499: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT03229499 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03229499, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side effects up to twelve months in pulmonary arterial hypertension (PAH).
Interventions
- DRUG Anastrozole
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-12-07 |
| Est. Completion | 2022-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03229499
The ClinicalTrials.gov registry entry for NCT03229499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anastrozole is the first listed.
NCT03229499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03229499 about?
NCT03229499 is a clinical study titled "Pulmonary Hypertension and Anastrozole Trial". The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side effects up to twelve months in pulmonary arterial hypertension (PAH).
What is the current status of trial NCT03229499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-12-07. Estimated completion is 2022-07-22.
What interventions are being tested in trial NCT03229499?
The interventions under investigation include: Anastrozole (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03229499?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.